Ketamine nasal spray shows promise against treatment-resistant depression
The trial is the first to compare esketamine against another commonly used add-on drug, authors say.
A nasal spray containing a ketamine derivative appears to beat one of the standard drugs for patients with treatment-resistant depression, a study has found.
The trial, of nearly 700 people with treatment-resistant depression, found that esketamine nasal spray was more effective at achieving remission than a standard oral drug quetiapine (Seroquel).
